IL-7 Modulates In Vitro and In Vivo Human Memory T Regulatory Cell Functions through the CD39/ATP Axis

Mehwish Younas, Sophie Hue, Christine Lacabaratz, Aurélie Guguin, Aurélie Wiedemann, Mathieu Surenaud, Stéphanie Beq, Thérèse Croughs, Jean-Daniel Lelièvre and Yves Lévy

*J Immunol* published online 21 August 2013
http://www.jimmunol.org/content/early/2013/08/21/jimmunol.1203547

Supplementary Material
http://www.jimmunol.org/content/suppl/2013/08/21/jimmunol.1203547.DC1

Why *The JI*?

- **Rapid Reviews!** 30 days* from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Speedy Publication!** 4 weeks from acceptance to publication

*average

Subscription
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
IL-7 Modulates In Vitro and In Vivo Human Memory T Regulatory Cell Functions through the CD39/ATP Axis

Mehwish Younas,*† Sophie Hue,*†±± Christine Lacabaratz,*†±± Aurélie Guguin,*†±± Aurélie Wiedemann,*†±± Mathieu Sureauad,*†±± Stéphanie Beq,* Thérèse Croughs,¶ Jean-Daniel Lelièvre,*†±±,§ and Yves Lévy*†±±,§

The heterogeneity of human regulatory T cells (Tregs) may explain the discrepancies between studies on Tregs in physiology and pathology. Contrasting effects of IL-7 on the expansion and survival of human Tregs were reported. Therefore, we investigated the effects of IL-7 on the phenotype and function of well-characterized populations of human Tregs. We show that IL-7 signals via the CD127 receptor on naive, memory, and activated memory Tregs sorted from the blood of healthy donors, but it does not affect their proliferation. In contrast, IL-7 affects their suppressive capacities differently. This effect was modest on naive Tregs but was dramatic (90%) on memory Tregs. We provide evidence that IL-7 exerts a synergistic effect through downmodulation of the ectoenzyme CD39, which converts ATP to ADP/AMP, and an increase in ATP receptor P2X7. Both effects lead to an increase in the ATP-mediated effect, tipping the balance to favor Th17 conversion. Using an IL-7 therapeutic study, we show that IL-7 exerts the same effects in vitro and in vivo in HIV-infected individuals. Globally, our data show that IL-7 negatively regulates Tregs and contributes to increase the number of tools that may affect Treg function in pathology. The Journal of Immunology, 2013, 191: 000–000.

CD4⁺ regulatory T cells (Tregs) mediate dominant and long-lasting tolerance. Recent studies showed that the phenotype and suppressive capacity of Tregs are highly heterogeneous. Human Tregs are described based on CD4, Foxp3, and high CD25 expression. In 2009, Miyara et al. (1) divided CD4⁺ Foxp3⁺ CD25⁺ cells into various subpopulations: resting or naive Tregs (nTregs; CD45RA⁺ Foxp3⁺ CD25⁺), activated memory or effector Tregs (CD45RA⁻ Foxp3⁺ CD25⁺/CD25⁺), and memory Tregs (CD45RA⁻ Foxp3⁺ CD25⁺). Moreover, it was shown that expression of CD127, the α-chain of the IL-7R, allows the distinction between CD127(low) Tregs and CD127(high) conventional T cells (2).

Different pathways and molecules involved in the suppression of immune activation are important to provide insight into the control of peripheral tolerance and to identify important therapeutic targets. Tregs may interfere directly with T effector function through several mechanisms. We (3) and other investigators (4, 5) recently described the involvement of CD39 in Treg function. CD39 is an ectoenzyme that, together with CD73, hydrolyzes extracellular pools of ATP into ADP and/or AMP to adenosine. Adenosine inhibits T cell proliferation and IL-2 production through adenosine receptor A2AR by stimulating the generation of cAMP. We reported that CD39 gene polymorphism is associated with a slower progression to AIDS, revealing this molecule as an important player in the suppression of anti-HIV responses (3).

Manipulation of Treg functions is an interesting therapeutic approach in numerous clinical settings. The use of cytokines may represent one way to modulate Treg function. The failure of IL-2 therapy during HIV infection has been linked to its ability to induce the proliferation of Tregs (6, 7), a property that has been used to improve hepatitis C virus–induced vasculitis (8). Recently, the role of other γc cytokines in Treg function and survival was investigated (9–19). Because Tregs are known to harbor low expression of CD127 (2), the role of this cytokine in Treg homeostasis has been ignored for a long time. However, several reports in mice and humans showed that IL-7 may impact the function and survival of Treg populations (9–19). However, precise mechanisms of action of IL-7 on Treg functions are still unclear.

One other important question regarding Tregs concerns their plasticity. Although they have been considered to represent stable populations, recent observations challenged this notion, suggesting that, under inflammatory conditions, they may acquire effector functions (20). Th17 CD4⁺ T cells, which express the transcription factor RORγt, belong to the third effector lineage of CD4⁺ T cells that develops independently of the classical Th1 and Th2 programs. Th17 cells and Tregs use reciprocal developmental pathways involving TGF-β (21). Although both cell types could compete for their differentiation from uncommitted T cells, recent reports showed that environmental factors could reverse Treg phenotype and function and redirect those cells toward a Th17 phenotype (22–25).

In this study, we investigated the role of IL-7 on the phenotype of Tregs and the expression of molecules involved in the suppressive
functions of these cells. We found that IL-7 relieves the suppressive effect of nonnaive Tregs by modulating the expression of CD39.

We showed an increased expression of RORγt and IL-17 mRNA and an increased production of IL-17. IL-7 also increased Treg expression of P2X7, a receptor of ATP, on activated Tregs (αTregs). We found that the Th17 switch of Tregs was blocked by antagonist expression. Globally, our results show that IL-7 exerts two synergistic effects on Tregs by modulating CD39 and increasing the ATP receptor, leading to a switch of Tregs toward a Th17 phenotype. Moreover, we found that in vivo administration of IL-7 tipped the balance toward a higher expression of RORγt in HIV-infected patients.

Materials and Methods

**Patient samples**

Peripheral blood samples were collected from HIV+ healthy donors seen at the Centre Regional de Transfusion Sanguine and from HIV-infected patients treated with antiretroviral therapy (c-ART) followed at Henri Mondor Hospital. Ethical committee approval and written informed consent from all subjects, in accordance with the Declaration of Helsinki, were obtained prior to study initiation. All HIV-infected patients were treated with c-ART, were virologically suppressed (viral load < 20 copies/ml), and had sustained CD4+ T cell restoration (CD4+ > 500/mm³). Blood samples were also obtained from nine HIV-infected patients who were treated with IL-7 (26). These patients, who had CD4 counts between 101 and 400 cells/mm³ and viral load < 50 copies/ml, received s.c. injections of rIL-7 on days 0, 7, and 14.

**Cell sorting**

Single-cell sorting was done with the MoFlo Legacy (Beckman Coulter, Marseille, France) to obtain various cell populations in sterile FACs tubes (BD Falcon). CD4+CD25+ cells were isolated using an isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), according to the manufacturer’s guidelines. The purity of isolated cells was checked after separation by FACs analysis.

**Flow cytometric analyses**

The following mAbs were used in the study: CD3 allophycocyanin H7 (SK7; BD Pharmingen, San Diego, CA), Foxp3 FITC (IC:1001; eBioScience, San Diego, CA), CD4 Pacific Blue (RA-P4T; BD Pharmingen), CD4 FITC (SFCLI12T1D11; Beckman Coulter), CD25 PE (4E3; Miltenyi Biotec), CD25 PC7 (B1.49.9; Beckman Coulter), CTLA4 PE (AAPO02; R&D Systems, Minneapolis, MN), GITR allophycocyanin (110416; R&D Systems), CD25 PC7 (B1.49.9; Beckman Coulter), and CD25 PE (100-714; BD Biosciences). The Live/Dead Fixable dead cells in all experiments.

**Cytokine measurement**

Cytokine production in the supernatant of the different subpopulations of Tregs was evaluated using a Lumine assay (Bio-Plex 200; Bio-Rad, Berkeley, CA). Purified CD4+CD25+ cells were incubated or not with IL-7 for 24 h; different Treg populations were sorted (see above) and incubated overnight with 2 μg/ml immobilized anti-CD3. Supernatant was collected and frozen at −80°C. The concentration of secreted IL-7 (Milliplex; Millipore, Billerica, MA) was measured in the supernatant (in pg/ml). The results were analyzed using Bio-Plex Manager 5 software (Bio-Rad).

**Real-time PCR**

Purified CD4+CD25+ cells were incubated or not with IL-7 for 24 h; different Treg populations were sorted (see above) and incubated for 24 h with 2 μg/ml immobilized anti-CD3. In some experiments, cells were incubated or not with 100 μM ATP (Sigma-Aldrich). Cells were harvested after 24 h, and total RNA was extracted using TRIzol reagent (Invitrogen). cDNA were synthesized using AffinityScript QPCR cDNA (StrataGen Systems). cDNA were then analyzed by RT-PCR using Brilliant II SYBR Green QPCR Master Mix (Agilent Technologies). The value of each sample was normalized to S14. The following primer sequences were used: S14: 5'-GGTCATCCGACCGAGATGAATCCTCAG-3'; 3'-CAGGTTTGGGTTGGTTGTGGTCC-5'; IL-17: 5'-TGGAAATCTCCACGCAATGAGGAC-3' and 3'-AGCGTTGATGCAGCCCAAGTAGGGA-5'; RORyt: 5'-GTCCCGGAGATGCTGGTCAAGT-3' and 3'-GACACTGGTCTCTTGTGGTCT-5'; and P2X7: 5'-AACCCTTCCCTTGGACGGGAAACT-3' and 3'-TGATGGGGGCCACCGAGGCA-5'.

**Statistical analysis**

All experiments were repeated at least three times. The Student paired two-tailed t test was used to determine the significance between two groups of samples. p value ≤ 0.05 was considered significant. All error bars represent SEM. All tests were performed using GraphPad Prism 4 software.

**Results**

IL-7 relieves the suppressive effect of memory Tregs

We first looked at the level of expression of CD127 on different Treg subpopulations (Fig. 1B) and analyzed their responsiveness to IL-7. Tregs were sorted from PBMCs according to their expression of P2X7, a receptor of ATP, leading to a switch of Tregs toward a Th17 phenotype. Moreover, we found that in vivo administration of IL-7 tipped the balance toward a higher expression of RORγt in HIV-infected patients.
expression (p < 0.05, before versus after IL-7, for all populations) (Fig. 2B, 2C).

In contrast, IL-7 was unable to induce the proliferation of Treg populations (Fig. 1D). Next we checked whether IL-7 modulates the suppressive effect of Tregs. Treg subpopulations incubated for 24 h with IL-7 were cocultured with purified CD8 T cells at a 1:4 ratio. Although IL-7 did not influence the suppressive effect of nTregs (25% decrease after IL-7, p = NS), we observed a dramatic decrease in the suppressive effect of both aTregs (70% decrease, p < 0.05) and memory Tregs (99% decrease, p < 0.05) after IL-7 preincubation (Fig. 2E, Supplemental Fig. 1). Globally, these results show that CD127 is functional on human Treg subpopulations and that IL-7 relieves the suppressive effect of memory Tregs.

**IL-7 decreases CD39 expression on memory Tregs**

Next we looked at whether IL-7 was able to modify the phenotype of Treg subpopulations. We first examined the modulation of the expression of several well-characterized molecules (CTLA-4, GITR, CD39, and PD-L1) involved in the Treg-mediated suppressive effect in Treg subpopulations after IL-7 incubation. IL-7 did not alter the expression of CTLA-4 on Tregs (Fig. 3A, Supplemental Fig. 2). We observed a slight, but insignificant, increase in PD-L1 on memory Tregs (p = 0.08, before versus after IL-7) (Fig. 3B). GITR expression was increased on aTregs and memory Tregs after IL-7 exposure (aTregs, p = 0.003; memory Tregs, p = 0.002, before versus after IL-7) (Fig. 3C). Finally, we found that IL-7 induced a decrease in CD39 expression on activated and memory Tregs (activated p < 0.001; memory p < 0.001; between before and after IL-7) (Fig. 3D). Because IL-7 did not induce a significant proliferation of Tregs (Fig. 2D), we conclude that IL-7 modifies the expression of molecules involved in the suppressive functions of activated and memory Tregs rather than a proliferation of expressing or nonexpressing cells.

Memory, but not naive, Tregs incubated in the presence of IL-7 acquire a Th17 phenotype

We showed that IL-7 decreased CD39 expression on Treg subpopulations and concomitantly modified their suppressive effect. We next wanted to analyze whether decreased CD39 expression was

---

**FIGURE 1.** Delineation of CD4<sup>+</CD25</sup> Treg populations. (A) Gating strategy of isolated CD4<sup>+</CD25</sup> cells at baseline. Four subsets were defined based on the expression of CD45RA, FOXP3, and CD127 (population I = nTregs; population II = aTregs; population III = memory Tregs; population IV = non-Tregs). (B) Representative expression of CD127 on different gated populations of CD4<sup>+</CD25</sup> cells [see (A)]. (C) Representative experiment showing the suppressive ability of sorted CD4<sup>+</CD25</sup> cell populations [see (A)] in coculture with autologous CFSE-stained CD8<sup>+</CD27</sup> cells for 5 d in the presence of immobilized anti-CD3.

**FIGURE 2.** Effect of IL-7 on CD4<sup>+</CD25</sup> cell populations. (A) Mean fluorescence intensity (MFI) expression of CD127 on the different CD4<sup>+</CD25</sup> cell subsets (population I = nTregs; population II = aTregs; population III = memory Tregs; population IV = non-Tregs) (n = 5). (B) Sorted CD4<sup>+</CD25</sup> cell subsets were incubated (black bars) or not (gray bars) with 10 ng/ml of IL-7. Expression of phosphorylated STAT-5 was assessed by flow cytometry analysis after 20 min (n = 3). (C) CD4<sup>+</CD25</sup> cells were sorted and cultured as in (B). Expression of Bcl-2 was assessed by flow cytometry analysis after 48 h (n = 3). (D) CD4<sup>+</CD25</sup> cells were sorted and stained with CFSE on day 0. CFSE staining was assessed after 5 d of culture with (black bars) or without (gray bars) IL-7 (n = 3). (E) Suppression assay showing percentage inhibition of effector T cell proliferation by different Treg populations after IL-7 treatment and then cocultured with CFSE-labeled effector CD8<sup>+</CD27</sup> T cells. Flow cytometric analysis was performed at day 5. The percentage of cells that was CFSE low was gated on CD8<sup>+</CD27</sup> T cell population (n = 4). Data are mean ± SEM. *p < 0.05, paired t test.
the only impact of IL-7 signaling on Tregs and whether this cytokine could change the fate of these cells, redirecting them toward a Th17 phenotype, as recently described for other cytokines (23). We first analyzed the production of IL-17 by Luminex assay (Materials and Methods). We found that IL-7 dramatically increased the production of IL-17 by activated and memory Tregs, whereas no change was noted for nTregs (Fig. 4A). We then analyzed the expression of IL-17 and RORγt mRNA, a key transcription factor for IL-17 expression, by Tregs after IL-7 exposure, focusing on the naive and activated populations. IL-7 induced an increase in both IL-17 and RORγt mRNA in aTregs, whereas it still had no effect on nTregs (Fig. 4B, 4C). Altogether, these results indicated that IL-7 is able to modify the phenotype of aTregs, decreasing their CD39 expression and redirecting them toward a Th17 phenotype through an increased expression of RORγt.

**IL-7 modulates memory Treg function through dual modification of the CD39/ATP axis**

We next investigated the functional consequences of the effects of IL-7 on the expression of CD39 on activated and memory Tregs and whether the ATP axis was involved in the shift of Tregs toward Th17 cells in the presence of IL-7. For this experiment, aTregs were cultured in the presence of IL-7, with (or without) anti-CD39 Abs blocking CD39 enzymatic function and ATP. We looked at the expression of IL-17 and RORγt mRNAs under these culture conditions. Anti-CD39 Ab, alone or in combination with ATP, was not able to modify RORγt expression, and it had a slight effect on IL-17 expression (Fig. 5A, 5B). In contrast, the adjunction of IL-7 to ATP induced a dramatic increase in the expression of both IL-17 and RORγt mRNA (Fig. 5C, 5D). Next, we looked at the expression of P2X7, a key receptor of ATP (23), and found a dramatic increase in its expression on aTregs in the presence of IL-7 (Fig. 5E). We used the P2X7 antagonist, pyridoxal phosphate-6-azophenyl-2′,4′-disulfonic acid (PPAD), to confirm that this effect could explain the increased production of IL-17 by aTregs treated with IL-7 (27). PPAD completely blocked the expression of the mRNA IL-17 and RORγt induced by IL-7 on aTregs (Fig. 6A, 6B). In contrast, PPAD was unable to reverse the suppressive effect of aTregs after IL-7 incubation (Fig. 5C). Altogether, these results indicated that IL-7 has a dual role on aTregs: it decreases...
The suppressive effect through a decrease in CD39 expression and redirects them toward a Th17 phenotype through an increase in the expression of the P2X7 receptor.

**Treatment with IL-7 decreases the percentage of memory Tregs and their expression of CD39 in vivo during HIV infection**

We recently showed the potential impact of IL-7 therapy during HIV infection (26, 28). We first studied the in vitro effect of IL-7 on Treg subsets from HIV-infected patients with undetectable viral load under c-ART. We found that IL-7 induced a decrease in CD39 expression on aTregs, as previously shown for HIV subjects. A decrease was also observed in memory Tregs, but this difference was not significant (Supplemental Fig. 3).

Then we analyzed the effect of IL-7 treatment on the evolution of Treg subsets in vivo. Cells were obtained from nine patients included in the INSPIRE trial (26). Treatment with IL-7 did not

**FIGURE 5.** ATP potentiates the effects of IL-7 on memory Tregs. (A) aTregs were sorted and incubated or not with purified 2 μg/ml anti-CD39 mAb (A1, Ozyme) at 37°C and/or with or without ATP 100 μM for 24 h. Total RNA was extracted, and real-time PCR was performed to analyze IL-17 expression. (B) Same as in (A) for RORγT expression. (C) Sorted memory Tregs were incubated (black bars) or not (gray bars) with IL-7 (10 ng/ml) for 24 h and cultured for another 24 h with or without ATP (100 μM). Total RNA was extracted, and real-time PCR was performed to analyze IL-17 expression. (D) Same as in (C) for RORγT expression. (E) nTregs (I) and aTregs (II) were incubated (black bars) or not (gray bars) with IL-7 for 24 h. P2X7 expression was assessed by RT-PCR. Data are mean ± SEM (n = 4). *p < 0.05, paired t test.

**FIGURE 6.** IL-7 increases the expression of P2X7 receptor on aTregs and redirects them toward a Th17 phenotype. (A) Activated sorted Tregs were incubated (black bars) or not (gray bars) with IL-7 for 24 h. Cells were also preincubated or not with ATP receptor blocker PPAD (20 μM; Sigma-Aldrich) for 2 h at 37°C and/or ATP (100 μM). IL-17 expression was assessed by RT-PCR analysis. (B) Same as (A) for RORγT expression. (C) Activated Tregs were sorted and incubated or not with 10 ng/ml IL-7 for 24 h and with ATP receptor blocker PPAD (20 μM) for 2 h and cocultured with autologous CFSE-stained CD8+ cells. The percentage of CD8+CFSElow+ cells was analyzed at 5 d. Data are mean ± SEM (n = 3). *p < 0.05, paired t test.
change the percentage of the total Treg population, whereas it increased the percentage of memory and activated cells among Tregs (data not shown). Tregs were purified from blood samples obtained before and after 12 wk of treatment with IL-7. First, we confirmed that in vitro incubation with IL-7 was able to decrease CD39 expression in memory Tregs (Fig. 7A). In eight patients for whom cells were available at day 0 and week 12, IL-7 therapy led to a decrease in CD39 expression on memory Tregs (Fig. 7B). Moreover, we found a correlation between the in vitro and ex vivo effects of IL-7 on CD39 expression on Tregs in the four patients for whom we had sufficient material to perform ex vivo and in vitro studies (these patients appear as □, ○, △, and × in Fig. 7A, 7B). Finally, we were able to perform mRNA analyses from purified Tregs from five patients in the INSPIRE study. Compared with baseline, we found a significant increase in both RORγT (Fig. 7C, \( p = 0.05 \)) and P2X7 (Fig. 7D, \( p < 0.01 \)) in Treg populations following IL-7 therapy.

Discussion

FOXP3+ Tregs are a heterogeneous population of CD4+ T cells that includes nTregs and aTregs, which were recently classified into diverse subpopulations by Miyara et al. (1). These populations seem to respond to different stimuli for their induction and survival (28). Although IL-2 was thought to be specifically involved in the generation and maintenance of nTregs, experiments in IL-2−/− and CD25−/− mice discussed this fact (29). Gene knockout of IL-2Rγc leads to a complete defect in CD4+FoxP3+ Tregs (30), a phenomenon in which the transcription factor STAT-5 is critically involved (31). Several recent reports indicated that IL-7 could be a determinant for the survival of Tregs (9–19). Like IL-2 and IL-15, IL-7 induces STAT-5 phosphorylation of Tregs in vitro (12, 14, 32). In mice, in vivo experiments showed that IL-7 primarily affects nTreg development (14, 16, 33). However, discrepancies about the role of IL-7 in Treg homeostasis remain. Some reports did not find a role for IL-7 in aTreg homeostasis (14), whereas others showed that it increases Treg numbers by inducing thymic-independent Treg peripheral expansion (17). Recently, Heninger et al. (34) showed that IL-7 could modify Treg functions. IL-7 induced phosphorylation of STAT-5 in naive and memory Tregs; promoted the proliferation of naive, but not memory, populations; and blocked the ability of Tregs to mediate suppression of effector T cells either after nonspecific or specific activation. However, the mechanisms involved in these phenomena remain unknown.

Our results significantly extend these previous studies. First, we report that IL-7, despite signaling the CD127 receptor on all Treg populations, did not increase the proliferation of these cells. This discrepancy with regard to other studies could result from the use of different coactivation systems in our study compared with the more potent activation signals delivered by anti-CD3 and anti-CD28 Abs. Second, we show that IL-7 decreases the suppressive effect of memory Tregs (up to 90%) but not nTregs (<25%). We clearly show that this effect relies on the modulation of the expression of the ectoenzyme CD39. As previously shown by our group (3) and other investigators (35), Tregs in mice constitutively express CD39, whereas the proportion of human CD39+ Tregs appears to be highly variable. We found that, although IL-7 signals both naïve and memory Tregs by increasing STAT-5 phosphorylation and Bcl-2 expression, this cytokine did not relieve the suppressive effect of nTregs that relies on their poor CD39 expression. CD39 and CD73 enzymes present on CD4+ CD25high T cells generate adenosine, a potent suppressor of effector T cell proliferation and function. CD39+ Tregs are thought to be involved in many clinical situations in humans, such as HIV and hepatitis B virus infections (3, 36), renal grafts, and cancer. CD39 blockade in mice (37) or in humans (3) was shown to impair their suppressive function. Our data contribute to increase the arsenal of tools that may affect Treg function by modulation of CD39 expression through external signals.

Recent data showed that the differentiation program of FoxP3+ Tregs is not fixed. Depending on the presence of external factors, these cells are able to differentiate into Th1 or Th17 cells (25). The presence of IL-6, an inflammatory cytokine produced by APCs, blocked the Treg-mediated suppressive effect (38), probably because of their conversion to Th17 cells (23). In addition to cytokines, other factors are known to be critical for peripheral Th17 differentiation. In mice, ATP produced by commensal bacteria promoted the presence of Th17 in the intestine and exacerbated T cell–mediated colitis (39). Recently Schenk et al. (23) showed that ATP mediates Treg conversion to Th17 cells through signaling via the P2X7 receptor, which can be increased by IL-6. We found that another cytokine, IL-7, redirects aTregs toward a Th17 phenotype. We clearly show that this effect relies on the modulation of the expression of the ectoenzyme CD39. As previously shown by our group (3) and other investigators (35), Tregs in mice constitutively express CD39, whereas the proportion of human CD39+ Tregs appears to be highly variable. We found that, although IL-7 signals both naïve and memory Tregs by increasing STAT-5 phosphorylation and Bcl-2 expression, this cytokine did not relieve the suppressive effect of nTregs that relies on their poor CD39 expression. CD39 and CD73 enzymes present on CD4+ CD25high T cells generate adenosine, a potent suppressor of effector T cell proliferation and function. CD39+ Tregs are thought to be involved in many clinical situations in humans, such as HIV and hepatitis B virus infections (3, 36), renal grafts, and cancer. CD39 blockade in mice (37) or in humans (3) was shown to impair their suppressive function. Our data contribute to increase the arsenal of tools that may affect Treg function by modulation of CD39 expression through external signals.
phenotype through an increase in P2X7 expression. In contrast to the study by Schenk et al. (23), we found that ATP/P2X7 seems to have minimal involvement in Treg-mediated suppressive activity (Fig. 5D). Therefore, we propose that IL-7 could have dual, but synergistic, effects through downmodulation of CD39 and an increase in P2X7 receptor. Both lead to an increase in the ATP-mediated effect, tipping the balance toward Th17 conversion.

What is the physiological relevance of this effect of IL-7 on T reg function? Thymus, skin, and the intestine are major sources of IL-7 (40). During the steady state, the majority of Th17 cells are located in the intestine where they are educated and can expand. Commensal bacteria may influence Th17 differentiation locally through ATP release (39), but they also may induce Tregs through TCR recognition of commensal Ags (41). We speculate that in physiology, IL-7 produced by intestinal epithelial cells could, in association with commensal bacteria of the microbiota, regulate the balance between αTregs and Th17 cells (42).

Finally, we (26, 43, 44) and other investigators (45–48) showed in several clinical trials in cancer or HIV that IL-7 increases Treg numbers, whereas their percentage among T cells decreases. Peligreni et al. (45) demonstrated that IL-7 administration during chronic viral infection leads to viral control. Notably, they found a large shift in the cytokine profile, an increase in the levels of IL-6 and IL-17, and a decrease in the level of immunosuppressive TGF-β. We showed in this study that IL-7 therapy decreases CD39 membrane expression and promotes expression of RORγt and P2X7 in αTregs, which sum up what we observed in vitro. Although these effects were not observed in all patients, overall we found an association between IL-7–mediated CD39 downregulation in vivo and in vitro. These differences could be the consequence of the presence of different polymorphisms of the IL-7R, which may induce differences in the responsiveness to IL-7 (44).

In conclusion, the results from this study extend our knowledge about the role of IL-7 in T cell homeostasis by dissecting its effects on subpopulations of memory Tregs. In contrast, these results contribute to improved characterization of these Treg subpopulations, showing that, beyond their phenotypic and functional heterogeneity, human Tregs could respond differently to external signals. Finally, convergent data show the modulation of memory Treg function through the ATP/CD39 axis. Previous in vitro studies that attempted to modulate these functions using blocking Abs or chemical products were performed by our group (3) and other investigators (35). We provide evidence that a therapeutic approach using IL-7, a cytokine in phase II clinical development, may also impact Treg phenotype comparably to in vitro effects. These observations reinforce the potential use of IL-7 in HIV infection characterized by an altered Treg/Th17 cell ratio.

Disclosures
S.B. and T.C. are employees of Cytheris, a company that develops IL-7 for therapeutic use. The other authors have no financial conflicts of interest.

References
4. Chen, X., L. Fang, S. Song, T. B. Guo, A. Liu, and Z. Zhang. 2008. Thymus, skin, and the intestine are major sources of IL-7 (40). During the steady state, the majority of Th17 cells are located in the intestine where they are educated and can expand. Commensal bacteria may influence Th17 differentiation locally through ATP release (39), but they also may induce Tregs through TCR recognition of commensal Ags (41). We speculate that in physiology, IL-7 produced by intestinal epithelial cells could, in association with commensal bacteria of the microbiota, regulate the balance between αTregs and Th17 cells (42).

Finally, we (26, 43, 44) and other investigators (45–48) showed in several clinical trials in cancer or HIV that IL-7 increases Treg numbers, whereas their percentage among T cells decreases. Peligreni et al. (45) demonstrated that IL-7 administration during chronic viral infection leads to viral control. Notably, they found a large shift in the cytokine profile, an increase in the levels of IL-6 and IL-17, and a decrease in the level of immunosuppressive TGF-β. We showed in this study that IL-7 therapy decreases CD39 membrane expression and promotes expression of RORγt and P2X7 in αTregs, which sum up what we observed in vitro. Although these effects were not observed in all patients, overall we found an association between IL-7–mediated CD39 downregulation in vivo and in vitro. These differences could be the consequence of the presence of different polymorphisms of the IL-7R, which may induce differences in the responsiveness to IL-7 (44).

In conclusion, the results from this study extend our knowledge about the role of IL-7 in T cell homeostasis by dissecting its effects on subpopulations of memory Tregs. In contrast, these results contribute to improved characterization of these Treg subpopulations, showing that, beyond their phenotypic and functional heterogeneity, human Tregs could respond differently to external signals. Finally, convergent data show the modulation of memory Treg function through the ATP/CD39 axis. Previous in vitro studies that attempted to modulate these functions using blocking Abs or chemical products were performed by our group (3) and other investigators (35). We provide evidence that a therapeutic approach using IL-7, a cytokine in phase II clinical development, may also impact Treg phenotype comparably to in vitro effects. These observations reinforce the potential use of IL-7 in HIV infection characterized by an altered Treg/Th17 cell ratio.


Supplementary Figure 1: Representative experiments showing the effect of IL-7 on the suppressive ability of CD4+CD25+ populations co-culture with autologous CFSE stained CD8+ for five days in presence of immobilized anti CD3.

Supplementary Figure 2: Histograms show a representative experiment of the expression of CTLA4, CD39, PDL1, GITR on the different CD4+CD25+ populations after (black) or not (grey) a 24h incubation with IL-7.

Supplementary figure 3 Percentage expression of CD39 on the different gated Treg cells subsets before (grey) and after (black) IL-7 (10ng/ml) incubation for 24hrs in HAART treated HIV+ patients (population I = Naive Treg; population II = activated Treg; population III = Memory Treg; population IV = non Treg). Results show means +/- SEM; statistical test= paired T test, *P<0.05, n=5
CD8+ cells alone

IL7-

IL7+

SI Figure 1 Younas et al
Supplementary Figure 2 Younas et al
Supplementary Figure 3 Younas et al